Gatikrushna Singh, Shilpi Singh, Iteeshree Mohapatra, Jay Hou, Andrew Ni, Debashis Barik, Haoyi Zheng, Stefan Kim, Mayur Sharma, Sean Lawler, Shobha Vasudevan, Efrosini Kokkoli, Sasmit Sarangi, Heinrich Elinzano, Eric T. Wong, Margot Martinez-Moreno, Ziya Gokaslan, Wafik El-Deiry, Clark C. Chen
. Temozolomide (TMZ) treatment induced cross-resistance to radiation and acquired resistance to TMZ; both forms of resistance were eliminated by RAD51 silencing or miR-181d transfection. Finally, the exogenous introduction of miR-181d in an immunocompetent murine glioblastoma model before radiation treatment induced anti-glioblastoma immune memory. These results support consideration for miR-181d-based glioblastoma therapy.